Dying patients gain access to experimental drugs blocked by federal scheduling

What it does

This bill amends the Controlled Substances Act to allow physicians to obtain a special registration from the Attorney General to directly administer Schedule I investigational drugs to terminally ill patients under the existing Federal Right to Try law. Physicians must demonstrate valid DEA registration, compliance with Right to Try requirements, state law authorization, and relevant training; the Attorney General must approve or deny applications within 45 days. Patients and physicians gain access to experimental drugs that have not completed FDA approval but show promise for serious conditions.

Why we flagged it

The bill's operative mechanism is to create a supervised administrative pathway for terminally ill patients to access investigational Schedule I drugs under existing Right to Try law. It is not deregulation (Schedule I status remains; DEA oversight continues) but rather a procedural accommodation within the existing regulatory framework.

What the text implies

• Interim final rule (240 days) bypasses normal notice-and-comment rulemaking, allowing rapid implementation before final rule is issued (2 years later). This accelerates access but reduces public input on enforcement details.
• Supplemental notification for additional drug quantities is 'deemed approved' after 30 days unless Attorney General objects—a soft approval mechanism that shifts burden to government to deny rather than physician to justify.
• Bill does not specify what 'diversion' prevention measures the Attorney General may impose, leaving enforcement scope undefined until rulemaking.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Terminally ill patients and their physicians gain expanded access to investigational drugs that may offer hope when standard treatments have failed, without weakening existing safety guardrails (manufacturer oversight, physician credentials, state law compliance, DEA record-keeping). The bill does not eliminate Schedule I status or safety review—it creates a narrow, supervised pathway within existing Right to Try law.

Who stands to gain

• Pharmaceutical manufacturers and sponsors (supply agreements for investigational drugs)
• Physicians (expanded scope of practice, potential revenue from Right to Try treatments)

Named in the bill

Attorney General, Controlled Substances Act, Schedule I drugs, Federal Right to Try law, Federal Food, Drug, and Cosmetic Act (section 561B), DEA (Drug Enforcement Administration), FDA (implied regulatory context)

Where it stands

18 cosponsors: 10 Democrats, 8 Republicans.

• Dec 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 4, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $200,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Madeleine Dean, the sponsor, reported $776,050 in PAC receipts in the 2026 cycle.

• Iraq and Afghanistan Veterans of America Inc — $120,000 on 1 filing
• Veteran Mental Health Leadership Coalition — $40,000 on 2 filings
• Reason for Hope — $20,000 on 1 filing
• Veteran Mental Health Leadership Coalition — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.